Publication:
The impact of visible tumor (PI-RADS >= 3) on upgrading and adverse pathology at radical prostatectomy in low risk prostate cancer patients: a biopsy core based analysis

Simple item page
dc.contributor.coauthorKilic, Mert
dc.contributor.coauthorSaglican, Yesim
dc.contributor.coauthorTugcu, Volkan
dc.contributor.coauthorBakir, Baris
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBalbay, Mevlana Derya
dc.contributor.kuauthorBaydar, Dilek Ertoy
dc.contributor.kuauthorCanda, Abdullah Erdem
dc.contributor.kuauthorÇil, Barbaros Erhan
dc.contributor.kuauthorEsen, Tarık
dc.contributor.kuauthorKiremit, Murat Can
dc.contributor.kuauthorKordan, Yakup
dc.contributor.kuauthorKöseoğlu, Ersin
dc.contributor.kuauthorÖzkan, Arif
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:37:28Z
dc.date.issued2022
dc.description.abstractDeciding on the management of prostate cancer (PCa), especially GG1 PCa, is quite difficult. The most important thing that will help us in making active surveillance or definitive treatment decision is whether the tumor is a clinically significant tumor. To understand this, we discussed in this article that multiparametric MR, PI-RADS scoring and targeted biopsy can be used. Background
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue1
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume20
dc.identifier.doi10.1016/j.clgc.2021.09.007
dc.identifier.eissn1938-0682
dc.identifier.issn1558-7673
dc.identifier.scopus2-s2.0-85118833159
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2021.09.007
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12834
dc.identifier.wos791221900016
dc.keywordsMultiparametric prostate magnetic resonance imaging
dc.keywordsFusion biopsy
dc.keywordsProstate cancer
dc.keywordsPi-Rads targeted biopsies
dc.keywordsDiagnosis
dc.keywordsImage
dc.language.isoeng
dc.publisherCig Media Group, Lp
dc.relation.ispartofClinical Genitourinary Cancer
dc.subjectOncology
dc.subjectUrology
dc.subjectNephrology
dc.titleThe impact of visible tumor (PI-RADS >= 3) on upgrading and adverse pathology at radical prostatectomy in low risk prostate cancer patients: a biopsy core based analysis
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorÖzkan, Arif
local.contributor.kuauthorKöseoğlu, Ersin
local.contributor.kuauthorBalbay, Mevlana Derya
local.contributor.kuauthorCanda, Abdullah Erdem
local.contributor.kuauthorKordan, Yakup
local.contributor.kuauthorKiremit, Murat Can
local.contributor.kuauthorEsen, Tarık
local.contributor.kuauthorBaydar, Dilek Ertoy
local.contributor.kuauthorÇil, Barbaros Erhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Collections

Publications without Fulltext